Skip to search formSkip to main contentSkip to account menu

SK-OV-3

An adenocarcinoma cell line established from the ascetic fluid of a 64 year old Caucasian female patient with ovarian carcinoma previously treated… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
PurposeAssessment of miR-424-3p mimic capability to sensitize SK-OV-3 and TOV-21G ovarian cancer cells to cisplatin by decreasing… 
2018
2018
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
PurposeThis study aimed at evaluating whether morin (a natural flavonoid and a known inhibitor of NF-κB) can sensitize ovarian… 
2016
2016
Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Highly Cited
2014
Highly Cited
2014
Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer.
2012
2012
Chemometric study of retention on binary stationary phases in gas chromatography.
Using gas chromatography, data analysis is performed on a dataset consisting of 486 retention indices, 27 standards (ramified… 
Highly Cited
2006
Highly Cited
2006
Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
2006
2006
Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
2005
2005
11,11′-Dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity
11,11′-Dideoxy-verticillin, a compound of the novel epidithiodioxopiprazine structural class, is isolated from the traditional… 
Highly Cited
1997
Highly Cited
1997
HER-2/neu Is Rate-limiting for Ovarian Cancer Growth
Amplification and overexpression of theHER-2/neu proto-oncogene frequently coincide with an aggressive clinical course of certain… 
Highly Cited
1993
Highly Cited
1993
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Amplification or overexpression of c-erbB-2/neu protooncogene, or both, occur frequently in many different types of human cancers… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License